Online inquiry

IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4988MR)

This product GTTS-WQ4988MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ITGA2B&ITGB3 gene. The antibody can be applied in Platelet aggregation research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000419.5; NM_000212.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3674; 3690
UniProt ID P08514; P05106
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ4988MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3651MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ12130MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-003
GTTS-WQ4703MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986168
GTTS-WQ10647MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3819253
GTTS-WQ10294MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LGT209
GTTS-WQ1534MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACE-031
GTTS-WQ3266MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ART621
GTTS-WQ7668MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GEN3013
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW